160 related articles for article (PubMed ID: 38278977)
1. Urinary microbiome-based metagenomic signature for the noninvasive diagnosis of hepatocellular carcinoma.
Cho EJ; Kim B; Yu SJ; Hong SK; Choi Y; Yi NJ; Lee KW; Suh KS; Yoon JH; Park T
Br J Cancer; 2024 Apr; 130(6):970-975. PubMed ID: 38278977
[TBL] [Abstract][Full Text] [Related]
2. Circulating Microbiota-Based Metagenomic Signature for Detection of Hepatocellular Carcinoma.
Cho EJ; Leem S; Kim SA; Yang J; Lee YB; Kim SS; Cheong JY; Cho SW; Kim JW; Kim SM; Yoon JH; Park T
Sci Rep; 2019 May; 9(1):7536. PubMed ID: 31101866
[TBL] [Abstract][Full Text] [Related]
3. The Intratumoral Bacterial Metataxonomic Signature of Hepatocellular Carcinoma.
Huang JH; Wang J; Chai XQ; Li ZC; Jiang YH; Li J; Liu X; Fan J; Cai JB; Liu F
Microbiol Spectr; 2022 Oct; 10(5):e0098322. PubMed ID: 36173308
[TBL] [Abstract][Full Text] [Related]
4. Distinct alterations of gut microbiota between viral- and non-viral-related hepatocellular carcinoma.
Jinato T; Anuntakarun S; Satthawiwat N; Chuaypen N; Tangkijvanich P
Appl Microbiol Biotechnol; 2024 Dec; 108(1):34. PubMed ID: 38183473
[TBL] [Abstract][Full Text] [Related]
5. A distinct microbiota signature precedes the clinical diagnosis of hepatocellular carcinoma.
Yang J; He Q; Lu F; Chen K; Ni Z; Wang H; Zhou C; Zhang Y; Chen B; Bo Z; Li J; Yu H; Wang Y; Chen G
Gut Microbes; 2023; 15(1):2201159. PubMed ID: 37089022
[TBL] [Abstract][Full Text] [Related]
6. Integrated analysis of microbiome and host transcriptome reveals correlations between gut microbiota and clinical outcomes in HBV-related hepatocellular carcinoma.
Huang H; Ren Z; Gao X; Hu X; Zhou Y; Jiang J; Lu H; Yin S; Ji J; Zhou L; Zheng S
Genome Med; 2020 Nov; 12(1):102. PubMed ID: 33225985
[TBL] [Abstract][Full Text] [Related]
7. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma.
Ren Z; Li A; Jiang J; Zhou L; Yu Z; Lu H; Xie H; Chen X; Shao L; Zhang R; Xu S; Zhang H; Cui G; Chen X; Sun R; Wen H; Lerut JP; Kan Q; Li L; Zheng S
Gut; 2019 Jun; 68(6):1014-1023. PubMed ID: 30045880
[TBL] [Abstract][Full Text] [Related]
8. Gut microbiome as a biomarker for predicting early recurrence of HBV-related hepatocellular carcinoma.
Zheng C; Lu F; Chen B; Yang J; Yu H; Wang D; Xie H; Chen K; Xie Y; Li J; Bo Z; Wang Y; Chen G; Deng T
Cancer Sci; 2023 Dec; 114(12):4717-4731. PubMed ID: 37778742
[TBL] [Abstract][Full Text] [Related]
9. Gut microbiome alteration as a diagnostic tool and associated with inflammatory response marker in primary liver cancer.
Deng T; Li J; He B; Chen B; Liu F; Chen Z; Zheng J; Shi Z; Zhang T; Deng L; Yu H; Yang J; Wu L; Shan Y; Yu Z; Chen X; Wang Y; Chen G
Hepatol Int; 2022 Feb; 16(1):99-111. PubMed ID: 35064546
[TBL] [Abstract][Full Text] [Related]
10. Gut microbial signatures of patients with primary hepatocellular carcinoma and their healthy first-degree relatives.
Feng J; Wu Y; Dai P; Wang D; Liu L; Chai B
J Appl Microbiol; 2023 Oct; 134(10):. PubMed ID: 37777841
[TBL] [Abstract][Full Text] [Related]
11. The diagnostic potential of gut microbiome for early hepatitis B virus-related hepatocellular carcinoma.
Tang Y; Zhou H; Xiang Y; Cui F
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e167-e175. PubMed ID: 33208683
[TBL] [Abstract][Full Text] [Related]
12. Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma.
Zeng Y; Chen S; Fu Y; Wu W; Chen T; Chen J; Yang B; Ou Q
J Viral Hepat; 2020 Feb; 27(2):143-155. PubMed ID: 31600845
[TBL] [Abstract][Full Text] [Related]
13. Identification of a brand intratumor microbiome signature for predicting prognosis of hepatocellular carcinoma.
Song Y; Xiang Z; Lu Z; Su R; Shu W; Sui M; Wei X; Xu X
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11319-11332. PubMed ID: 37380815
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive evaluation of microRNA as a biomarker for the diagnosis of hepatocellular carcinoma.
Malik J; Klammer M; Rolny V; Chan HL; Piratvisuth T; Tanwandee T; Thongsawat S; Sukeepaisarnjaroen W; Esteban JI; Bes M; Köhler B; Swiatek-de Lange M
World J Gastroenterol; 2022 Aug; 28(29):3917-3933. PubMed ID: 36157551
[TBL] [Abstract][Full Text] [Related]
15. Alterations in the Gut Microbiome in the Progression of Cirrhosis to Hepatocellular Carcinoma.
Lapidot Y; Amir A; Nosenko R; Uzan-Yulzari A; Veitsman E; Cohen-Ezra O; Davidov Y; Weiss P; Bradichevski T; Segev S; Koren O; Safran M; Ben-Ari Z
mSystems; 2020 Jun; 5(3):. PubMed ID: 32546668
[TBL] [Abstract][Full Text] [Related]
16. Gut microbiota dysbiosis with hepatitis B virus liver disease and association with immune response.
Yan F; Zhang Q; Shi K; Zhang Y; Zhu B; Bi Y; Wang X
Front Cell Infect Microbiol; 2023; 13():1152987. PubMed ID: 37201112
[TBL] [Abstract][Full Text] [Related]
17. Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma.
Zheng R; Wang G; Pang Z; Ran N; Gu Y; Guan X; Yuan Y; Zuo X; Pan H; Zheng J; Wang F
Cancer Med; 2020 Jun; 9(12):4232-4250. PubMed ID: 32281295
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Gut Microbiota and Exploration of Potential Predictive Model for Hepatocellular Carcinoma Microvascular Invasion.
Zhang N; Wang Z; Lv J; Zhang S; Liu Y; Liu T; Li W; Gong L; Zhang X; El-Omar EM; Lu W
Front Med (Lausanne); 2022; 9():836369. PubMed ID: 35372388
[TBL] [Abstract][Full Text] [Related]
19. Human microbiome is a diagnostic biomarker in hepatocellular carcinoma.
Rao BC; Lou JM; Wang WJ; Li A; Cui GY; Yu ZJ; Ren ZG
Hepatobiliary Pancreat Dis Int; 2020 Apr; 19(2):109-115. PubMed ID: 32037278
[TBL] [Abstract][Full Text] [Related]
20. Metabolic syndrome cannot mask the changes of faecal microbiota compositions caused by primary hepatocellular carcinoma.
Ni J; Fu C; Huang R; Li Z; Li S; Cao P; Zhong K; Ge M; Gao Y
Lett Appl Microbiol; 2021 Jul; 73(1):73-80. PubMed ID: 33768575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
